CA2362787A1 - Nouveaux agents de fixation d'oxydoreduction et leurs utilisations - Google Patents

Nouveaux agents de fixation d'oxydoreduction et leurs utilisations Download PDF

Info

Publication number
CA2362787A1
CA2362787A1 CA002362787A CA2362787A CA2362787A1 CA 2362787 A1 CA2362787 A1 CA 2362787A1 CA 002362787 A CA002362787 A CA 002362787A CA 2362787 A CA2362787 A CA 2362787A CA 2362787 A1 CA2362787 A1 CA 2362787A1
Authority
CA
Canada
Prior art keywords
cells
redox
butyrate
agents
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362787A
Other languages
English (en)
Inventor
Edward J. Yurkow
Fred H. Mermelstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2362787A1 publication Critical patent/CA2362787A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des agents de fixation d'oxydoréduction permettant de maintenir des cellules dans un état d'oxydoréduction donné. Cette invention concerne également des procédés d'utilisation de ces agents de fixation d'oxydoréduction destinés à sensibiliser les cellules à des agents chimiothérapeutiques comme les antinéoplasiques, de manière à inhiber l'hyperprolifération desdites cellules et à stabiliser l'état d'oxydoréduction des cellules dont l'état d'oxydoréduction fluctue de manière anormale.
CA002362787A 1999-02-16 2000-02-15 Nouveaux agents de fixation d'oxydoreduction et leurs utilisations Abandoned CA2362787A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12012899P 1999-02-16 1999-02-16
US60/120,128 1999-02-16
PCT/US2000/003878 WO2000048632A1 (fr) 1999-02-16 2000-02-15 Nouveaux agents de fixation d'oxydoreduction et leurs utilisations

Publications (1)

Publication Number Publication Date
CA2362787A1 true CA2362787A1 (fr) 2000-08-24

Family

ID=22388429

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362787A Abandoned CA2362787A1 (fr) 1999-02-16 2000-02-15 Nouveaux agents de fixation d'oxydoreduction et leurs utilisations

Country Status (5)

Country Link
EP (1) EP1159004A4 (fr)
JP (1) JP2002537273A (fr)
AU (1) AU775066B2 (fr)
CA (1) CA2362787A1 (fr)
WO (1) WO2000048632A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006058183A1 (de) 2006-11-29 2008-06-05 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verwendung von Substanzen, die den zellulären Glutathion-Gehalt absenken, zur Herstellung eines Arzneimittels zur Behandlung von T-Zell vermittelten Autoimmunkrankheiten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1185551B (it) * 1985-04-15 1987-11-12 Schering Spa Composizioni farmaceutiche a base di acido mercaptoetansolfonico ad attivita' terapeutica,derivati salini organici dell'acido mercaptoetansolfonico utili per tali composizioni e relativo procedimento di preparazione
NZ266640A (en) * 1993-04-30 1998-01-26 Pacific Northwest Research Fou Diagnosing genotoxic or carcinogenic status by analysing cellular redox potential where increased risk is indicated when the potential favours oxidatively derived modified nucleotides
DE4435661C2 (de) * 1994-10-05 1998-07-02 Deutsches Krebsforsch Mittel zur Behandlung von Papillomvirus-positiven gutartigen, malignen und prämalignen Läsionen

Also Published As

Publication number Publication date
WO2000048632A1 (fr) 2000-08-24
AU3491500A (en) 2000-09-04
AU775066B2 (en) 2004-07-15
EP1159004A4 (fr) 2004-04-21
EP1159004A1 (fr) 2001-12-05
JP2002537273A (ja) 2002-11-05

Similar Documents

Publication Publication Date Title
Thirunavukkarasu et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase
Chirino et al. Protective effects of apocynin against cisplatin-induced oxidative stress and nephrotoxicity
Zou et al. Expression and actions of heme oxygenase in the renal medulla of rats
Li et al. GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway
Cortese-Krott et al. Silver ions induce oxidative stress and intracellular zinc release in human skin fibroblasts
Cantoni et al. Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity
Kim et al. Functional dissection of Nrf2-dependent phase II genes in vascular inflammation and endotoxic injury using Keap1 siRNA
Choi et al. Carbon monoxide prevents TNF-α-induced eNOS downregulation by inhibiting NF-κB-responsive miR-155-5p biogenesis
Wei et al. Effects of co-administration of antioxidants and arsenicals on the rat urinary bladder epithelium
Buglak et al. Cinnamic aldehyde inhibits vascular smooth muscle cell proliferation and neointimal hyperplasia in Zucker Diabetic Fatty rats
Heilman et al. Transactivation of gene expression by NF-κB is dependent on thioredoxin reductase activity
Yang et al. Depletion of cytosolic or mitochondrial thioredoxin increases CYP2E1-induced oxidative stress via an ASK-1–JNK1 pathway in HepG2 cells
Lu et al. Oncogenic Akt-FOXO3 loop favors tumor-promoting modes and enhances oxidative damage-associated hepatocellular carcinogenesis
Siems et al. Oxidative stress in chronic lymphoedema
Ozyigit et al. Different dose-dependent effects of ebselen in-sciatic nerve ischemia-reperfusion injury in rats
Umar et al. Pharmacological activation of autophagy restores cellular homeostasis in ultraviolet-(B)-induced skin photodamage
Yeh et al. Cardiomyocytic apoptosis limited by bradykinin via restoration of nitric oxide after cardioplegic arrest
Zheng et al. Differential regulation of human ALAS1 mRNA and protein levels by heme and cobalt protoporphyrin
Huang et al. Biliverdin reductase A protects lens epithelial cells against oxidative damage and cellular senescence in age-related cataract
Balasubramaniyan et al. Mouse recombinant leptin protects human hepatoma HepG2 against apoptosis, TNF-α response and oxidative stress induced by the hepatotoxin–ethanol
Talaverón-Rey et al. Alpha-lipoic acid supplementation corrects pathological alterations in cellular models of pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels
Vig-Varga et al. Alpha-lipoic acid modulates ovarian surface epithelial cell growth
Schirris et al. Stimulation of cholesterol biosynthesis in mitochondrial complex I-deficiency lowers reductive stress and improves motor function and survival in mice
AU775066B2 (en) Novel redox clamping agents and uses thereof
Achuth et al. Nitrosoglutathione triggers collagen deposition in cutaneous wound repair

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued